Bellerophon Therapeutics (BLPH) Upgraded to “Buy” by Zacks Investment Research - Fairfield Current

Bellerophon Therapeutics (BLPH) Upgraded to “Buy” by Zacks Investment Research  Fairfield Current

Bellerophon Therapeutics (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on ...



Comments

Popular posts from this blog

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Analysis: Large pharma companies do little new drug innovation - STAT